文献速递头颈外科

p16阳性口咽鳞癌TORS术后局部区域复发分析

Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
PubMed 文献 · Laryngoscope · 2021-06-02

该回顾性研究分析了2007至2017年间541例完成经口机器人手术(TORS)及指南依从辅助治疗的HPV相关口咽鳞状细胞癌(HPV+ OPSCC)患者,发现5年局部区域复发(LRR)率仅4.5%,无明确临床病理特征与LRR相关;

要点

  • HPV+ OPSCC完成TORS及指南依从辅助治疗后5年LRR率低(4.5%)。
  • 辅助放疗可降低LRR风险(HR 0.28),但未改善DFS或OS。
  • 发生LRR者5年OS显著低于无LRR者(67.1% vs 93.9%)。

核心结论

  • HPV+ OPSCC完成TORS和指南依从辅助治疗后LRR率低,无辅助治疗指征者更易发生LRR,但复发通常可通过挽救治疗控制。

研究设计与样本

  • 单中心回顾性分析2007至2017年完成原发性TORS、颈清扫及NCCN指南依从辅助治疗的HPV+ OPSCC患者541例。

主要发现

  • 541例完成指南指示治疗的患者估计5年LRR率为4.5%。
  • 未发现与LRR相关的可识别临床或病理特征。
  • 初始接受辅助放化疗者及发生局部、野内和/或咽后淋巴结复发者挽救治疗后疾病控制率降低。

临床怎么用

  • 对于完成TORS和指南依从辅助治疗的HPV+ OPSCC患者,LRR率低,可据此进行预后咨询。
  • 无辅助治疗指征者LRR风险较高,但复发多可通过挽救治疗控制,支持辅助治疗降阶梯试验的探索。
  • 发生LRR者生存预后较差,尤其是初始接受辅助放化疗及特定复发模式者,需加强随访和挽救治疗策略。

局限性

  • 单中心回顾性研究,证据等级为3级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the patterns, risk factors, and salvage outcomes for locoregional recurrences (LRR) after treatment with transoral robotic surgery (TORS) for HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC). STUDY DESIGN: Retrospective analysis of HPV+ OPSCC patients completing primary TORS, neck dissection, and NCCN-guideline-compliant adjuvant therapy at a single institution from 2007 to 2017. METHODS: Features associated with LRR, detailed patterns of LRR, and outcomes of salvage therapy were analyzed. Disease-free survival (DFS) and overall survival (OS) were calculated for subgroups of patients receiving distinct adjuvant treatments. RESULTS: Of 541 patients who completed guideline-indicated therapy, the estimated 5-year LRR rate was 4.5%. There were no identifiable clinical or pathologic features associated with LRR. Compared to patients not receiving adjuvant therapy, those who received indicated adjuvant radiation alone had a lower risk of LRR (HR 0.28, 95% CI [0.09-0.83], P = .023), but there was no difference in DFS (P = .21) and OS (P = .86) between adjuvant therapy groups. The 5-year OS for patients who developed LRR was 67.1% vs. 93.9% for those without LRR (P < .001). Patients who initially received adjuvant chemoradiation and those suffering local, in-field, and/or retropharyngeal node recurrences had decreased disease control after salvage therapy. CONCLUSION: LRR rates are low for HPV+ OPSCCs completing TORS and guideline-compliant adjuvant therapy. Patients without indication for adjuvant therapy more often suffer LRR, but these recurrences are generally controllable by salvage therapy. Improved understanding of the patterns of recurrence most amenable to salvage therapy may guide treatment decisions, counseling, and adjuvant therapy de-escalation trials. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E2865-E2873, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Carey RM, Brody RM, Shimunov D, et al. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS. Laryngoscope. 2021. PMID: 34076275. doi:10.1002/lary.29659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。